[203-Pb] VMT-NET

N/A

Report date: 2025/11/20 13:28:15
NME

Base Information

Drug Name[203-Pb] VMT-NET
Drug Alias NameVMT-NET[203 Pb] VMT-NET[203Pb] VMT alpha NET203Pb radioactive imaging agent(Viewpoint Molecular Targeting)203Pb VMT-α-GEN +[10] 
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Lead > 203PbRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionSomatostatin receptor 2 bindersRadionuclide imaging enhancersSingle-photon emission-computed tomography enhancers
TargetsSomatostatin receptor 2
Therapy Area/IndicationsSmall Cell Lung CarcinomaHead and Neck NeoplasmsCarcinoma, Renal Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPerspective Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPerspective Therapeutics IncNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaHead and Neck NeoplasmsCarcinoma, Renal Cell +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A